期刊
BIOMATERIALS
卷 32, 期 31, 页码 8029-8039出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2011.07.021
关键词
Polymethacrylic acid; Controlled drug release; Immunomodulation; Infection; Antimicrobial; Drug delivery
资金
- NIH (US) [1U01A1075726]
- UK Williams Trust [AP-117]
- NIHR
- UK Wellcome Trust [078223MA]
- Biotechnology and Biological Sciences Research Council [BB/H022406/1] Funding Source: researchfish
- BBSRC [BB/H022406/1] Funding Source: UKRI
Cutaneous leishmaniasis (CL) is a neglected tropical disease that causes prominent skin scaring. No water soluble, non-toxic, short course and low cost treatment exists. We developed a new water soluble amphotericin B-polymethacrylic acid (AmB-PMA) using established and scalable chemistries. AmB-PMA was stable for 9 months during storage. In vitro, it was effective against Leishmania spp. promastigotes and amastigote infected macrophages. It was also less toxic and more effective than deoxycholate-AmB, and similar to liposomal AmB. Its in vivo activity was determined in both early and established CL lesion models of Leishmania major infection in genetically susceptible non-healing BALB/c mice. Intradermal AmB-PMA at a total dose of 18 mg of AmB/kg body weight led to rapid parasite killing and lesion healing. No toxicity was seen. No parasite relapse occurred after 80 days follow-up. Histological studies confirmed rapid parasite clearance from macrophages followed by accelerated fibroblast mediated tissue repair, regeneration and cure of the infection. Quantitative mRNA studies of the CL lesions showed that accelerated healing was associated with increased Tumour Necrosis Factor-alpha and Interferon-gamma, and reduced Interleukin-10. These results suggest that a cost-effective AmB-PMA could be used to pharmacologically treat and immuno-therapeutically accelerate the healing of CL lesions. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据